Ticker >

Norris Medicines share price

Norris Medicines Ltd.

BSE: 524414 SECTOR: Pharmaceuticals & Drugs  5289   3   0

13.60
+0.63 (4.86%)
BSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 13.6

Today's Low

₹ 12.71

52 Week High

₹ 27.51

52 Week Low

₹ 10.05

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

13.6 Cr.

Enterprise Value

34.98 Cr.

No. of Shares

1 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -13.73

CASH

0.02 Cr.

DEBT

21.4 Cr.

Promoter Holding

34.01 %

EPS (TTM)

₹  -1.91

Sales Growth

-11.44%

ROE

0 %

ROCE

3.17%

Profit Growth

46.39 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.44%
3 Year2.14%
5 Year-9.24%

Profit Growth

1 Year46.39%
3 Year11.45%
5 Year5.45%

ROE%

1 Year0%
3 Year0%
5 Year-27.69%

ROCE %

1 Year3.17%
3 Year-7.09%
5 Year-9.82%

Debt/Equity

-1.7202

Price to Cash Flow

11.34

Interest Cover Ratio

0.204616893896866

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 34.01 0
Sep 2023 34.01 0
Jun 2023 34.01 0
Mar 2023 34.04 0
Dec 2022 34.04 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 23.7787512164552 days.

 Limitations

  • The company has shown a poor revenue growth of 2.1402374877558% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of -7.09383644664825% over the past 3 years
  • The company has a low EBITDA margin of -6.99969415975983% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 3.16 1.21 0.95 2.56 0.65
Total Expenditure 2.83 0.67 1.33 2.8 0.69
Operating Profit 0.34 0.55 -0.39 -0.25 -0.04
Other Income 0 0.01 0 0 0
Interest 0.39 0.37 0.09 0.09 0.09
Depreciation 0.15 0.18 0.14 0.15 0.15
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.2 0.01 -0.62 -0.48 -0.27
Tax 0 0.56 0 0 0
Profit After Tax -0.2 -0.54 -0.62 -0.48 -0.27
Adjusted EPS (Rs) -0.2 -0.55 -0.62 -0.48 -0.27

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 16.27 7.84 12.25 9.44 8.36
Total Expenditure 16.88 10 14 9.51 7.44
Operating Profit -0.61 -2.16 -1.74 -0.07 0.92
Other Income 0.04 0.09 0.05 0.03 0.01
Interest 0.73 0.88 1.63 1.48 1.5
Depreciation 0.71 0.73 0.67 0.66 0.63
Exceptional Items 0 0 0 0 0
Profit Before Tax -2.01 -3.68 -3.99 -2.18 -1.19
Tax -0.33 -0.84 0.97 1.08 0.56
Net Profit -1.68 -2.84 -4.96 -3.26 -1.75
Adjusted EPS (Rs.) -1.69 -2.86 -5 -3.29 -1.76

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 9.93 9.93 9.93 9.93 9.93
Total Reserves -9.55 -12.39 -17.36 -20.62 -22.37
Borrowings 11.24 14.98 15.52 18.1 18.43
Other N/C liabilities -2.82 -3.66 -2.69 -1.61 -1.05
Current liabilities 8.77 8.04 11.69 6.78 7.7
Total Liabilities 17.57 16.9 17.1 12.58 12.63
Assets
Net Block 8.9 8.25 7.67 7.07 6.47
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.01
Loans & Advances 1.26 1.2 1.19 1.23 1.23
Other N/C Assets 0 0 0 0 0
Current Assets 7.4 7.44 8.23 4.27 4.92
Total Assets 17.57 16.9 17.1 12.58 12.63
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations -2.01 -3.68 -3.99 -2.18 -1.19
Adjustment 1.42 1.59 2.29 2.13 2.12
Changes in Assets & Liabilities -1.33 -0.79 2.82 -0.95 0.27
Tax Paid 0 0 0 0 0
Operating Cash Flow -1.92 -2.88 1.11 -1.01 1.2
Investing Cash Flow -0.29 0 -0.06 -0.09 -0.02
Financing Cash Flow 2.18 2.86 -1.09 1.1 -1.18
Net Cash Flow -0.02 -0.02 -0.04 0 0

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 34.04 34.04 34.01 34.01 34.01
milind l upadhyaya 0.01 0.01 0.01 0.01 0.01
navnit jethabhai patel 0.04 0.04 0.04 0.04 0.04
navsarjan investment & tr... 10.00 10.00 10.00 10.00 10.00
nimish bhishma thakore - - 0.01 0.01 0.01
vimal d shah 23.60 23.60 23.60 23.60 23.60
vimal dhirendra shah - 0.34 0.34 0.34 0.34
nimish b thakore 0.04 0.04 - - -
vimal dhirendra shah huf 0.34 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 65.96 65.96 65.99 65.99 65.99
fab metals private limite... 41.99 41.99 41.99 41.99 41.99
lkp securities limited 1.50 1.50 1.50 1.50 1.50

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Norris Medicines informs about outcome of directors meeting22 Mar 2024, 5:24PM Norris Medicines - Quaterly Results14 Feb 2024, 3:40PM Norris Medicines - Quaterly Results14 Feb 2024, 3:40PM Norris Medicines informs about closure of trading window 29 Sep 2023, 4:55PM Norris Medicines - Quaterly Results10 Aug 2023, 4:40PM Norris Medicines - Quaterly Results10 Aug 2023, 4:40PM Norris Medicines informs about issuance of duplicate share certificate14 Jun 2023, 4:55PM Norris Medicines - Quaterly Results25 May 2023, 3:37PM Norris Medicines - Quaterly Results25 May 2023, 3:37PM Norris Medicines - Quaterly Results25 May 2023, 3:37PM Norris Medicines informs about outcome of board meeting13 Feb 2023, 4:38PM Norris Medicines - Quaterly Results13 Feb 2023, 12:39PM Norris Medicines - Quaterly Results13 Feb 2023, 12:39PM Norris Medicines - Quaterly Results13 Feb 2023, 12:39PM Norris Medicines informs about unaudited financial results11 Nov 2022, 5:14PM Norris Medicines - Quaterly Results11 Nov 2022, 11:25AM Norris Medicines informs about outcome of board meeting15 Sep 2022, 5:13PM Norris Medicines - Quaterly Results27 Aug 2022, 5:27PM Norris Medicines - Quaterly Results27 Aug 2022, 5:27PM Norris Medicines - Quaterly Results27 Aug 2022, 5:27PM Norris Medicines - Quaterly Results25 May 2022, 2:54PM Norris Medicines - Quaterly Results25 May 2022, 2:54PM Norris Medicines - Quaterly Results25 May 2022, 2:54PM Norris Medicines informs about PCS certificate20 Apr 2022, 4:48PM Norris Medicines informs about compliance certificate5 Apr 2022, 5:02PM Norris Medicines - Quaterly Results12 Feb 2022, 1:50PM Norris Medicines informs about trading window closure31 Dec 2021, 3:49PM Norris Medicines informs about book closure28 Aug 2021, 2:38PM Norris Medicines informs about notice of 30th AGM 28 Aug 2021, 12:59PM Norris Medicines informs about compliance certificate5 Jul 2021, 12:50PM Norris Medicines informs about non-applicability of annual secretarial compliance report28 Jun 2021, 4:25PM Norris Medicines informs about board meeting 19 Jun 2021, 11:35AM Norris Medicines informs about demise of independent director 24 May 2021, 12:34PM Norris Medicines submits certificate20 Apr 2021, 3:30PM Norris Medicines informs about compliance certificate3 Oct 2020, 3:47PM Norris Medicines submits voting result of AGM26 Sep 2020, 3:53PM Norris Medicines informs about disclosure of material impact of covid-191 Jun 2020, 3:52PM

Norris Medicines Stock Price Analysis and Quick Research Report. Is Norris Medicines an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Norris Medicines and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Norris Medicines cash from the operating activity was Rs 1.1995167 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Norris Medicines has a Debt to Equity ratio of -1.7202 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Norris Medicines , the EPS growth was 46.3913136044284 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Norris Medicines has OPM of 11.035243911993 % which is a bad sign for profitability.
     
  • ROE: Norris Medicines have a poor ROE of 0 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Norris Medicines is Rs 13.6. One can use valuation calculators of ticker to know if Norris Medicines share price is undervalued or overvalued.
Last Updated on:
Brief about Norris Medicines
X